Skip to main content
Erschienen in: International Urology and Nephrology 6/2019

24.04.2019 | Nephrology - Original Paper

Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis

verfasst von: Tadej Petreski, Robert Ekart, Radovan Hojs, Sebastjan Bevc

Erschienen in: International Urology and Nephrology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hyperuricemia has been associated with higher mortality in the general population, but less is known about CKD patients. The aim of our study was to determine the impact of elevated serum uric acid on cardiovascular mortality of CKD patients who later progress to hemodialysis.

Methods

In this retrospective study, 120 CKD patients (entire population of patients with ESKD on January 1st, 2012) were observed from their first visit at the Nephrology outpatient clinic, while transitioning to hemodialysis, and until their death or January 1, 2016. After non-cardiovascular death exclusion, 83 CKD patients (33 female, 50 male) were left for further analysis. The average time of observation was 8.8 ± 4.2 years. Serum uric acid was measured regularly (every 3 months). No patients were treated for hyperuricemia. Mean uric acid of 420 µmol/L was set as a cut-off between normouricemic and hyperuricemic patients as per the laboratory’s reference values. Survival rates were analyzed using Kaplan–Meier survival curves. Three Cox regression models were used to assess the influence of uric acid on survival.

Results

Mean uric acid was 379.8 ± 71.6 µmol/L (range 220–574). Sixty-three (75.9%) patients were normouricemic and 20 (24.1%) were hyperuricemic. Cholesterol was the only variable to show statistically significant difference (p = 0.004) between the groups. Bivariate analysis revealed an association between death and age, hyperuricemia, arterial hypertension, and history of cardiovascular disease. Kaplan–Meier survival analysis showed higher risk of cardiovascular death for hyperuricemic patients (log rank test; p < 0.0005). In Cox regression models, hyperuricemia remained a predictor of cardiovascular mortality (SE = 0.500, Exp(B) = 14.120, 95% CI 5.297–37.640) in our patients next to age and arterial hypertension.

Conclusion

The results indicate an association between hyperuricemia and cardiovascular mortality in CKD patients who transition to hemodialysis.
Literatur
3.
Zurück zum Zitat Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28:2221–2228CrossRefPubMedPubMedCentral Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28:2221–2228CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ohno I (2011) Relationship Between Hyperuricemia and Chronic Kidney Disease. Nucleosides Nucleotides Nucleic Acids 30:1039–1044CrossRefPubMed Ohno I (2011) Relationship Between Hyperuricemia and Chronic Kidney Disease. Nucleosides Nucleotides Nucleic Acids 30:1039–1044CrossRefPubMed
5.
Zurück zum Zitat Mallat SG, Al Kattar S, Tanios BY, Jurjus A (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74CrossRefPubMed Mallat SG, Al Kattar S, Tanios BY, Jurjus A (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74CrossRefPubMed
6.
Zurück zum Zitat Ferri C (2017) The problem of cardio-renal diseases in patients with gout. Curr Med Res Opin 33(sup3):9–13CrossRefPubMed Ferri C (2017) The problem of cardio-renal diseases in patients with gout. Curr Med Res Opin 33(sup3):9–13CrossRefPubMed
7.
Zurück zum Zitat Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res. 8(5):551–554CrossRefPubMedPubMedCentral Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res. 8(5):551–554CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bardin T, Richette P (2014) Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 26(2):186–191CrossRefPubMed Bardin T, Richette P (2014) Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 26(2):186–191CrossRefPubMed
9.
Zurück zum Zitat Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17(3):13CrossRefPubMed Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17(3):13CrossRefPubMed
10.
Zurück zum Zitat Karis E, Crittenden DB, Pillinger MH (2014) Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J 107(4):235–241CrossRefPubMed Karis E, Crittenden DB, Pillinger MH (2014) Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J 107(4):235–241CrossRefPubMed
11.
12.
Zurück zum Zitat Butkovič M (2016) Urate as a potential risk factor of cardiovascular and renal diseases. Acta Med Croatica. 70:233–239PubMed Butkovič M (2016) Urate as a potential risk factor of cardiovascular and renal diseases. Acta Med Croatica. 70:233–239PubMed
13.
Zurück zum Zitat Nashar K, Fried LF (2012) Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk Factor? Adv Chronic Kidney Dis. 19:386–391CrossRefPubMed Nashar K, Fried LF (2012) Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk Factor? Adv Chronic Kidney Dis. 19:386–391CrossRefPubMed
14.
Zurück zum Zitat Momoki K, Kataoka H, Moriyama T, Mochizuki T, Nitta K (2017) Hyperuricemia as a predictive marker for progression of nephrosclerosis: clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis. J Atheroscler Thromb. 24(6):630–642CrossRefPubMedPubMedCentral Momoki K, Kataoka H, Moriyama T, Mochizuki T, Nitta K (2017) Hyperuricemia as a predictive marker for progression of nephrosclerosis: clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis. J Atheroscler Thromb. 24(6):630–642CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Buzas R, Tautu OF, Dorobantu M, Ivan V, Lighezan D (2018) Serum uric acid and arterial hypertension-Data from Sephar III survey. PLoS ONE 13(7):e0199865CrossRefPubMedPubMedCentral Buzas R, Tautu OF, Dorobantu M, Ivan V, Lighezan D (2018) Serum uric acid and arterial hypertension-Data from Sephar III survey. PLoS ONE 13(7):e0199865CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Petreski T, Bevc S, Ekart R, Hojs R (2017) Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis. Clin Nephrol 88(13):69–72CrossRefPubMed Petreski T, Bevc S, Ekart R, Hojs R (2017) Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis. Clin Nephrol 88(13):69–72CrossRefPubMed
17.
Zurück zum Zitat Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M et al (2016) The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol 68(5):384–391CrossRefPubMed Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M et al (2016) The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol 68(5):384–391CrossRefPubMed
18.
Zurück zum Zitat Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370CrossRefPubMed Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370CrossRefPubMed
19.
Zurück zum Zitat Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL et al (2011) Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 6(10):2470–2477CrossRefPubMedPubMedCentral Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL et al (2011) Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 6(10):2470–2477CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kim CS, Jin DC, Yun YC, Bae EH, Ma SK, Kim SW (2017) Relationship between serum uric acid and mortality among hemodialysis patients: retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 36(4):368–376CrossRefPubMedPubMedCentral Kim CS, Jin DC, Yun YC, Bae EH, Ma SK, Kim SW (2017) Relationship between serum uric acid and mortality among hemodialysis patients: retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 36(4):368–376CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 15:122–134CrossRefPubMedPubMedCentral Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 15:122–134CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ (2015) Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort Study. PLoS ONE 10(12):e0145193CrossRefPubMedPubMedCentral Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ (2015) Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort Study. PLoS ONE 10(12):e0145193CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bevc S, Zorman T, Purg D, Ekart R, Hojs R (2013) Cardiovascular mortality and microinflammation in abdominal obese hemodialysis patients. Acta Medico-Biotechnica. 6(2):39–46 Bevc S, Zorman T, Purg D, Ekart R, Hojs R (2013) Cardiovascular mortality and microinflammation in abdominal obese hemodialysis patients. Acta Medico-Biotechnica. 6(2):39–46
24.
Zurück zum Zitat Li M, Li X, Liu Y, Liu X, Song Y, Zhao J et al (2018) Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta 486:156–161CrossRefPubMed Li M, Li X, Liu Y, Liu X, Song Y, Zhao J et al (2018) Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta 486:156–161CrossRefPubMed
25.
Zurück zum Zitat Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T et al (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 295(4):F1134–F1141CrossRefPubMedPubMedCentral Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T et al (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 295(4):F1134–F1141CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Piko N, Ekart R, Bevc S, Hojs R (2017) Atherosclerosis, epigenetic modifications, and arterial stiffness. Acta Medico-Biotechnica. 10(2):10–17 Piko N, Ekart R, Bevc S, Hojs R (2017) Atherosclerosis, epigenetic modifications, and arterial stiffness. Acta Medico-Biotechnica. 10(2):10–17
27.
Zurück zum Zitat Sedaghat S, Hoorn EJ, van Rooij FJ, Hofman A, Franco OH, Witteman JC et al (2013) Serum uric acid and chronic kidney disease: the role of hypertension. PLoS ONE 8(11):e76827CrossRefPubMedPubMedCentral Sedaghat S, Hoorn EJ, van Rooij FJ, Hofman A, Franco OH, Witteman JC et al (2013) Serum uric acid and chronic kidney disease: the role of hypertension. PLoS ONE 8(11):e76827CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Postorino M, Marino C, Tripepi G, Zoccali C (2011) Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int 79(7):765–772CrossRefPubMed Postorino M, Marino C, Tripepi G, Zoccali C (2011) Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney Int 79(7):765–772CrossRefPubMed
30.
Metadaten
Titel
Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis
verfasst von
Tadej Petreski
Robert Ekart
Radovan Hojs
Sebastjan Bevc
Publikationsdatum
24.04.2019
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 6/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02154-w

Weitere Artikel der Ausgabe 6/2019

International Urology and Nephrology 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.